Susanne Viktoria Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susanne Viktoria Schmidt has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
- Jasper Spitzer
Institute of Innate Immunity, Medical Faculty, University of Bonn, Bonn, Germany
61 shared publications - Abed Rahman Kawakibi
University of Michigan, Ann Arbor, Michigan
58 shared publications - Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
58 shared publications - Akash Deogharkar
University of Michigan, Ann Arbor, Michigan
58 shared publications - Alexander R. Judkins
Children's Hospital Los Angeles
58 shared publications - Alyssa Waugh
University of Michigan, Ann Arbor, Michigan
58 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
NK cell immunosurveillance and CX3CL1-CX3CR1 axis perturbations in ETV6::RUNX1 positive preleukemia and BCP-ALL
- 29 September 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
Open AccessNK cell immunosurveillance and CX3CL1-CX3CR1 axis perturbations in ETV6::RUNX1 positive preleukemia and BCP-ALL
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Unbiased assessment of 2-arachidonoylglycerol in cardiovascular inflammation
2-arachidonoylglycerol (2-AG) is an endogenous modulator of inflammatory processes. Recent studies demonstrate its key role in inflammatory cardiovascular diseases, such as atherosclerosis and left ventricular remodelling. However, whether 2-AG acts as a pro- or anti-inflammatory agent in cardiovascular inflammation is a matter of controversial debate. CD14 + primary human monocytes were treated with 2-AG. Differentially expressed genes were determined by mRNA sequencing and used for bioinformatics analysis of changes in myeloid cell functions and cell signalling pathways. Additionally, we quantified cytokines and mediators involved in cardiac remodelling by multiplexing assays. Human monocytes responded to the treatment with 2-AG by inducing a pro-inflammatory cellular program. The top upregulated hallmark pathways were TNFα signalling via the NF-κB pathway, the inflammatory response and IL-6 signalling, illustrating the pro-inflammatory mode of action of 2-AG. These data were validated at the protein level in the supernatants of stimulated cells using multiplexing assays. Based on these in-vitro results, we examined blood samples from patients during acute and chronic coronary syndromes. By sampling blood from both the periphery and the culprit coronary artery, we observed a trend towards higher local concentrations of the cardiac remodelling factors Galectin-3, Osteopontin, and IP-10 in the coronary arteries of patients presenting with acute coronary syndrome compared with other groups. The levels of these remodelling factors correlate positively with 2-AG levels. Taken together, our data suggest that 2-AG acts as a pro-inflammatory agent in myocardial infarction and LV remodelling.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1)
Open AccessUnbiased assessment of 2-arachidonoylglycerol in cardiovascular inflammation
2-arachidonoylglycerol (2-AG) is an endogenous modulator of inflammatory processes. Recent studies demonstrate its key role in inflammatory cardiovascular diseases, such as atherosclerosis and left ventricular remodelling. However, whether 2-AG acts as a pro- or anti-inflammatory agent in cardiovascular inflammation is a matter of controversial debate. CD14 + primary human monocytes were treated with 2-AG. Differentially expressed genes were determined by mRNA sequencing and used for bioinformatics analysis of changes in myeloid cell functions and cell signalling pathways. Additionally, we quantified cytokines and mediators involved in cardiac remodelling by multiplexing assays. Human monocytes responded to the treatment with 2-AG by inducing a pro-inflammatory cellular program. The top upregulated hallmark pathways were TNFα signalling via the NF-κB pathway, the inflammatory response and IL-6 signalling, illustrating the pro-inflammatory mode of action of 2-AG. These data were validated at the protein level in the supernatants of stimulated cells using multiplexing assays. Based on these in-vitro results, we examined blood samples from patients during acute and chronic coronary syndromes. By sampling blood from both the periphery and the culprit coronary artery, we observed a trend towards higher local concentrations of the cardiac remodelling factors Galectin-3, Osteopontin, and IP-10 in the coronary arteries of patients presenting with acute coronary syndrome compared with other groups. The levels of these remodelling factors correlate positively with 2-AG levels. Taken together, our data suggest that 2-AG acts as a pro-inflammatory agent in myocardial infarction and LV remodelling.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual patients with H3K27M-mutant DMG treated with ONC201.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
ONC201 dosage chart for patients younger than 18 years of age.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Individual cases from historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
VST-transformed gene expression values for all samples and protein-coding genes.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Summary of historical control datasets.
- Open Access
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
- 18 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.